Teriparatide peptide is a distinctive recombinant peptide osteoanabolic drug. Its core advantages stem from its precise peptide molecular structure: rather than being the intact hormone, it is an active peptide segment that replicates the 1–34 amino acids at the N-terminus of human endogenous parathyroid hormone (PTH). It retains the core function of promoting bone formation while avoiding adverse reactions associated with long-term use of the intact hormone, embodying the distinct characteristics of peptide drugs-high efficacy, target specificity, and low toxicity.
Our high-quality products
Teriparatide COA
Therapeutic Application in Fibrous Dysplasia (FD) of Bone
Fibrous dysplasia of bone is a benign tumor-like bone lesion caused by somatic activating mutations of the GNAS gene. Its core pathological feature is the replacement of normal bone tissue with abnormally proliferative fibrous tissue and woven bone, leading to reduced bone mass, disrupted bone microarchitecture, and increased bone fragility. Common clinical manifestations include bone pain, skeletal deformity, and pathological fractures.
In severe cases, it may impair joint function or even compress adjacent nerves and blood vessels, severely affecting patients' quality of life. Traditional treatments for FD are mainly surgical intervention (curettage and osseous grafting, deformity correction) and symptomatic analgesia.
However, therapeutic options are limited for patients with multifocal lesions, those intolerant to surgery, or those with postoperative recurrence.
With its potent osteoanabolic effects, Teriparatide peptide provides a novel strategy for FD management, particularly in improving bone quality, relieving bone pain, and reducing fracture risk.
01.Pathogenesis and Therapeutic Challenges of Fibrous Dysplasia
The central pathogenesis of FD involves somatic activating mutations in the GNAS gene, leading to abnormal GTPase activity of the encoded G protein α-subunit (Gsα), which in turn causes overactivation of the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling pathway.
This results in abnormal proliferation of bone marrow mesenchymal stem cells (BMSCs) and impaired osteogenic differentiation, ultimately leading to massive accumulation of abnormal fibrous tissue and immature woven bone that replaces normal osseous .
Such pathological changes significantly reduce osseous mechanical strength and predispose to pathological fractures. Meanwhile, abnormal bone tissue stimulates peripheral nerve endings, causing persistent bone pain and severely limiting mobility.
Current clinical management of FD faces multiple challenges: for monofocal, localized lesions, curettage and bone grafting is the first-line treatment, but the postoperative recurrence rate is high (approximately 15%–30%), and graft fusion is highly dependent on baseline bone quality. For multifocal lesions or those involving weight-bearing bones or craniofacial bones, surgery is technically difficult and highly invasive, making complete resection unattainable.
Although bisphosphonates can alleviate bone pain, they cannot reverse bone microarchitectural damage or reduce the risk of pathological fractures.
Nonsteroidal anti-inflammatory drugs only provide temporary pain relief without targeting the underlying cause, and long-term use may induce gastrointestinal adverse reactions.
Therefore, there is an urgent clinical need for a therapeutic agent that can improve bone quality, enhance bone strength, and fundamentally alleviate FD progression. The emergence of it offers a promising solution to this dilemma.
PMC article (Diagnosis and Management of Monostotic Fibrous Dysplasia of the Tibia in an Adolescent Patient: A Case Report); MDPI article (PTHrP Modulates the Proliferation and Osteogenic Differentiation of Craniofacial Fibrous Dysplasia-Derived BMSCs).
02.Mechanism of Action in FD Treatment
Targeting the pathological features of FD, it exerts therapeutic effects through multiple pathways, with the core actions of improving the differentiation of abnormal BMSCs, promoting normal bone formation, and inhibiting abnormal fibrous tissue proliferation. The specific mechanisms fall into three main categories.First, it regulates the differentiation direction of BMSCs. BMSCs in FD patients show abnormal differentiation, with excessive differentiation toward fibroblasts and insufficient osteogenic commitment.
By binding to PTH receptors on BMSCs, Teriparatide peptide activates the Wnt/β-catenin signaling pathway and suppresses excessive cAMP/PKA pathway activation, thereby correcting abnormal BMSC differentiation. This directs BMSCs toward osteogenic lineage, reduces abnormal fibrous tissue formation, increases osteoblast number and activity, and facilitates normal bone repair.
Second, it improves bone microarchitecture and enhances bone strength. Lesional osseous in FD is dominated by immature woven bone and fibrous tissue, with sparse, fractured trabeculae and thinned cortices, resulting in markedly reduced mechanical strength.
Intermittent administration of it stimulates osteoblasts to synthesize bone matrix, increasing trabecular thickness, bone volume fraction, and trabecular number while reducing trabecular separation.
It repairs damaged bone microarchitecture and promotes the transformation of woven bone into mature lamellar bone, significantly strengthening lesional bone mechanics and lowering pathological fracture risk.
Third, it relieves bone pain and improves patient mobility. Bone pain in FD mainly arises from nerve irritation by abnormal bone tissue and mechanical instability caused by microarchitectural disruption.
It reduces neural compression by promoting normal osseous formation and repairing damaged osseous structure. Its osteoanabolic effect also improves skeletal mechanical stability, alleviate weight-bearing pain, thereby enhancing mobility and quality of life.
In vitro studies confirm that it significantly improves osteogenic differentiation of FD patient-derived BMSCs and reduces the expression of abnormal fibrous tissue markers.
MDPI article (PTHrP Modulates the Proliferation and Osteogenic Differentiation of Craniofacial Fibrous Dysplasia-Derived BMSCs);Chinese Expert Consensus on drug for Osteoporotic Fractures (2024 Edition) (Chinese Medical Journal Full-text Database);NCBI Bookshelf (Tariparatide - StatPearls).
Application in Enhancing the Stability of Orthopaedic Implants
Orthopaedic implants (such as artificial joints, fracture fixation devices, bone graft scaffolds, etc.) have been widely used in orthopaedic surgeries including fracture fixation, joint replacement and osseous defect repair. Their stability directly determines surgical outcomes and patient prognosis.
Insufficient implant stability tends to cause implant loosening, displacement and breakage, which further lead to complications such as surgical failure, periprosthetic fracture and infection.
These complications often require revision surgery, increasing both patient suffering and medical costs.With its potent osteoanabolic effect, Teriparatide peptide can promote osseointegration between the implant and host bone and improve bone quality around the implant, thereby significantly enhancing the long‑term stability of orthopaedic implants, reducing the incidence of complications and optimizing surgical prognosis.
China Medical Information Query Platform (Fuqin'ao Tariparatide);China Medical Information Query Platform (Recombinant Tariparatide for Injection);NCBI Bookshelf (Tariparatide - StatPearls).
Common Adverse Reactions
Common adverse reactions of it mainly involve injection-site and systemic reactions. Injection-site reactions include pain, swelling, erythema, local bruising, pruritus, and mild bleeding, which are mostly transient and resolve gradually with continued treatment; rotating injection sites can reduce such reactions.
Systemic reactions mainly include nausea, limb pain, headache, dizziness, palpitations, anemia, dyspnea, and depression, with incidence rates similar to those in the placebo group. Most occur early in treatment, are mild in severity, and do not require treatment discontinuation.
In addition, it may cause slight elevations in serum calcium and uric acid levels. In clinical trials, 2.8% of patients had serum uric acid concentrations above the upper limit of normal, but this did not increase the incidence of gout, arthralgia, or urolithiasis.
Hypercalcemia is usually transient and requires no specific management.
However, if patients develop symptoms related to hypercalcemia (e.g., nausea, vomiting, constipation, polyuria), medical attention should be sought promptly for dose adjustment or treatment cessation.
MDPI, Tariparatide Therapy as an Adjuvant for Tissue Engineering and Integration of Biomaterials;Journal of Orthopaedic Case Reports, Tariparatide Treatment Improved Loosening of Cementless Total Knee Arthroplasty: A Case Report.
I. High-Performance Liquid Chromatography (HPLC): Basic Assay for Content and Purity
High-performance liquid chromatography is the most commonly used basic analytical method for it, mainly applied for peptide content determination and purity screening.
It offers the advantages of simple operation, good reproducibility, and high sensitivity.
Detection is typically performed using a C18 column (e.g., Kromasil C18, 4.6 mm × 250 mm, 5 μm), with a mobile phase consisting of 0.05 mol·L⁻¹ potassium chloride solution (adjusted to pH 4.5 with phosphoric acid) and acetonitrile at a ratio of 75:25.
The flow rate is controlled at 1.0 mL·min⁻¹, detection wavelength at 210 nm, column temperature at room temperature, and injection volume at 20 μL. This method enables effective separation of it from impurities. It shows excellent linearity (r = 0.9999) in the concentration range of 0.05–0.84 mg·mL⁻¹, allowing accurate determination of drug content and preliminary purity screening.
In addition, in accordance with the requirements of the European Pharmacopoeia (EP 9.0), a hydrophilic silica gel packed column can be used to separate impurities with molecular weights greater than tariparatide, ensuring satisfactory separation efficiency.
Academic Achievements Database of Hainan Medical University (Study on the determination of tariparatide by high-performance liquid chromatography);Shodex Literature (Analysis of Tariparatide According to EP Method (KW-802.5)).
II. Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS): Accurate Identification and Quantitation of Impurities
Due to the limitations of HPLC-UV in impurity identification, which cannot clarify the structures of co-eluting impurities, liquid chromatography-high resolution mass spectrometry has become the core technique for impurity analysis of Teriparatide peptide.
Combining the separation power of chromatography with the high specificity and sensitivity of mass spectrometry, this method allows simultaneous detection, separation, and quantitation of process-related and degradation-related impurities, such as oxidative degradation products and peptide fragments.
Experiments have confirmed that the method exhibits good linearity in the concentration range of 500 to 10,000 ng/mL (r² = 0.9998), with precision (%RSD) below 2.0%.
The limit of detection and limit of quantitation are as low as 0.02% and 0.05% of the label claim, respectively, far below the regulatory reporting threshold (0.10%).
It can accurately identify impurities such as tariparatide oxidative degradation products and 1–30 amino acid fragments, providing critical support for drug purity control.
The Center for Research on Complex Generics (CRCG) Literature (Therapeutic Tariparatide Quality Control by Liquid Chromatography Mass Spectrometry);PubMed Literature (Validation of a liquid chromatography-high-resolution mass spectrometry method to quantify peptide-related impurities in tariparatide).
III. Peptide Mapping Analysis (LC-UV-MS): Structural Confirmation and Sequence Verification
Peptide mapping is the core method for structural confirmation of tariparatide. Through enzymatic hydrolysis, chromatographic separation, and hyphenated mass spectrometry, it achieves full verification of the peptide sequence and confirmation of the primary structure. The procedure is as follows: tariparatide is first subjected to enzymatic hydrolysis, then the hydrolysate fragments are separated using various columns (e.g., C18, phenylhexyl columns), and finally identified by a high-resolution QTOF mass spectrometer, achieving 100% sequence coverage.
By comparing the peptide maps (retention time, peak height, resolution) of the sample and the reference standard, this method confirms the primary structure of teriparetide and identifies modified products such as oxidation and deamidation, ensuring that the drug structure is consistent with the active fragment of natural parathyroid hormone. It is a key technique for comparing structural consistency between generic drugs and the reference listed drug.
Sigma-Aldrich Literature (Teriparetide Mapping Analysis by LC-UV-MS);MDPI Literature (First Generic Teriperatide: Structural and Biological Sameness to Its Reference Medicinal Product).
IV. LC-MS/MS Method: Detection in Clinical Serum Samples
For clinical monitoring, accurate determination of teriparetide concentration in human serum is required, for which ultra-high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) is commonly used.
In this method, tariparatide in serum is extracted by solid-phase extraction, with rat PTH 1–34 fragment as the internal standard, and detected using multiple charge ion monitoring.
The total run time is only 4.0 min, with a linear range of 15.07–913.3 pg/mL (correlation coefficient ≥ 0.99). Both precision and accuracy meet the requirements for bioanalytical assays.
Without the need for antibodies, this method effectively reduces interference from non-specific binding.
It has been successfully applied in clinical bioequivalence studies, enabling rapid analysis of large numbers of serum samples and providing data support for the adjustment of clinical dosage regimens.
PubMed Literature (Bioanalytical method development and validation of highly selective and sensitive LC-MS/MS method for determination of tariparatide in human serum).
Hot Tags: teriparatide peptide, China teriparatide peptide manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, desmopressin acetate 0 1 mg, glp1 shot, etelcalcetide structure
